Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2022

Voorhees Peter M, Jakubowiak Andrzej J, Kumar Shaji K, Kanapuru Bindu, Baines Andrea C, Bhatnagar Vishal, Ershler Rachel, Theoret Marc R, Gormley Nicole J, Pazdur Richard

Abstract excerpt

The multiple myeloma treatment landscape has evolved considerably over the last 20 years with the development of multiple therapies with novel mechanisms of action and new combination regimens. However, the recent failure of several large phase III trials, coupled with an increased understanding of the mutational landscape of multiple myeloma has provided opportunities to explore optimal strategies for future...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Development
Share to Multiple Myeloma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Precision Medicine

Source

Identifiers

PMID: 34315721
DOI: 10.1158/1078-0432.CCR-21-1069

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.PMID 34315721Read ↗

[Towards precision medicine in myeloma: new evidence and challenges].Semantic proximity Read ↗

Where we were, where we are, where we are going: progress in multiple myeloma.Semantic proximity Read ↗

Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution ExperienceSemantic proximity Read ↗

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useSemantic proximity Read ↗

Multiple myeloma.Semantic proximity Read ↗

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple MyelomaSemantic proximity Read ↗

Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment.Semantic proximity Read ↗

Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity Read ↗

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read ↗

Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple MyelomaSemantic proximity Read ↗

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity Read ↗

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.